Paclitaxel

Generic Name: Paclitaxel

Brand Names: Abraxane, Taxol, Naveruclif, Pazenir, Apexelsin

Drug Type: Small Molecule

Chemical Formula: C_₄₇H_₅₁NO_₁₄

CAS Number: 33069-62-4

Unique Ingredient Identifier: P88XT4IS4D

Background: Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.

Indication: Used in the treatment of Kaposi's sarcoma and cancer of the lung, ovarian, and breast. Abraxane® is specfically indicated for the treatment of metastatic breast cancer and locally advanced or metastatic non-small cell lung cancer.

Associated Conditions: Advanced Cervical Cancer, Advanced Head and Neck Cancer, Advanced Ovarian Cancer, Advanced Soft Tissue Sarcoma, Esophageal Cancer, Fallopian Tube Cancer, Gastric Cancer, Kaposi's Sarcoma, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Bladder Cancer, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Adenocarcinoma Metastatic, Peritoneal Cancer, Recurrent Small Cell Lung Cancer (SCLC), Advanced Bladder cancer, Advanced Thymoma, Metastatic Penile cancer, Refractory Testicular germ cell cancer

Associated Therapies: -

Clinical Trials

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Phase 3

Completed

Conditions: Recurrent Melanoma
Stage IIIC Skin Melanoma
Mucosal Melanoma
Stage IIIA Skin Melanoma
Stage IIIB Skin Melanoma
Stage IV Skin Melanoma

Interventions: Drug: Carboplatin
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Other: Pharmacological Study
Drug: Sorafenib Tosylate
Other: Placebo

First Posted Date: 2005-05-04

Last Posted Date: 2015-10-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 823

Registration Number: NCT00110019

Locations: 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸
Bay Area Tumor Institute, Oakland, California, United States
🇺🇸
Kaiser Permanente-Redwood City, Redwood City, California, United States

and more 216 locations

Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer

Phase 3

Conditions: Fallopian Tube Endometrioid Adenocarcinoma
Ovarian Brenner Tumor
Ovarian Clear Cell Adenocarcinoma
Fallopian Tube Mucinous Adenocarcinoma
Ovarian Seromucinous Carcinoma
Stage IIIB Primary Peritoneal Cancer AJCC v7
Stage IIIC Fallopian Tube Cancer AJCC v7
Stage IIIC Primary Peritoneal Cancer AJCC v7
Fallopian Tube Clear Cell Adenocarcinoma
Fallopian Tube Undifferentiated Carcinoma

Interventions: Other: Clinical Observation
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel
Drug: Paclitaxel Poliglumex
Procedure: Quality-of-Life Assessment

First Posted Date: 2005-04-19

Last Posted Date: 2021-09-30

Lead Sponsor: GOG Foundation

Target Recruit Count: 1157

Registration Number: NCT00108745

Locations: 🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Mount Carmel Health Center West, Columbus, Ohio, United States
🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States

and more 312 locations

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction

Phase 2

Completed

Conditions: Esophageal Cancer

Interventions: Drug: bortezomib
Drug: carboplatin
Drug: paclitaxel

First Posted Date: 2005-04-06

Last Posted Date: 2016-12-13

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 37

Registration Number: NCT00107341

AZD2171 + Chemotherapy in Advanced NSCLC, Colorectal Cancer, or Other Cancer Suitable for Treatment With Capecitabine (Non-Small Lung Cancer Patients Closed to Enrollment as 8/9/07)

Phase 1

Completed

Conditions: Lung Cancer
Colorectal Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: capecitabine
Drug: carboplatin
Drug: cediranib maleate
Drug: paclitaxel

First Posted Date: 2005-04-06

Last Posted Date: 2023-08-04

Lead Sponsor: NCIC Clinical Trials Group

Target Recruit Count: 50

Registration Number: NCT00107250

Locations: 🇨🇦
Ottawa Hospital Regional Cancer Centre - General Campus, Ottawa, Ontario, Canada
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

Phase 3

Active, not recruiting

Conditions: Teratoma
Extragonadal Germ Cell Tumor
Testicular Germ Cell Tumor

Interventions: Biological: bleomycin sulfate
Drug: cisplatin
Drug: etoposide
Drug: ifosfamide
Drug: oxaliplatin
Drug: paclitaxel

First Posted Date: 2005-03-04

Last Posted Date: 2024-02-06

Lead Sponsor: UNICANCER

Target Recruit Count: 263

Registration Number: NCT00104676

Locations: 🇺🇸
M. D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇫🇷
Centre Henri Becquerel, Rouen, France
🇸🇰
National Cancer Institute - Bratislava, Bratislava, Slovakia

and more 21 locations

Intraperitoneal tgDCC-E1 and Intravenous Paclitaxel in Women With Platinum-Resistant Ovarian Cancer

Phase 1

Terminated

Conditions: Ovarian Cancer

Interventions: Biological: Intraperitoneal tgDCC-E1A
Drug: Paclitaxel

First Posted Date: 2005-02-01

Last Posted Date: 2018-11-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 18

Registration Number: NCT00102622

Locations: 🇺🇸
University of Texas M. D. Anderson Cancer Center, Houston, Texas, United States

S0329, Gemcitabine and Paclitaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: gemcitabine
Drug: paclitaxel

First Posted Date: 2005-01-07

Last Posted Date: 2012-10-01

Lead Sponsor: SWOG Cancer Research Network

Target Recruit Count: 67

Registration Number: NCT00100789

Locations: 🇺🇸
Holland Community Hospital, Holland, Michigan, United States
🇺🇸
University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸
St. John's Regional Health Center, Springfield, Missouri, United States

and more 119 locations

Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)

Phase 2

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Biological: Cetuximab
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2004-11-19

Last Posted Date: 2010-04-09

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 165

Registration Number: NCT00097227

Locations: 🇺🇸
ImClone Investigational Site, Morgantown, West Virginia, United States

Randomized Amifostine For SCCHN

Phase 2

Completed

Conditions: Head and Neck Cancer
Mucositis
Chemotherapeutic Agent Toxicity
Radiation Toxicity
Xerostomia

Interventions: Drug: Amifostine
Drug: Carboplatin
Radiation: radiation
Drug: Paclitaxel

First Posted Date: 2004-11-09

Last Posted Date: 2017-01-04

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 58

Registration Number: NCT00095927

Locations: 🇺🇸
Goodall Hospital, Sanford, Maine, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 6 locations

Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer

Phase 2

Completed

Conditions: Recurrent Ovarian Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Primary Peritoneal Carcinoma

Interventions: Drug: Sorafenib Tosylate
Drug: Carboplatin
Drug: Paclitaxel

First Posted Date: 2004-11-09

Last Posted Date: 2022-02-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 44

Registration Number: NCT00096200

Locations: 🇺🇸
Moffitt Cancer Center at Tampa General Hospital, Tampa, Florida, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States

and more 2 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy